News Releases | Upcoming Events | Webcast/Presentation Archive

View printer-friendly version << Back

Turkey’s Leading University Hospital Adopts Masimo SpHb for Continuous Noninvasive Haemoglobin Monitoring

06/30/15

NEUCHÂTEL, Switzerland--(BUSINESS WIRE)--Jun. 30, 2015-- Masimo (NASDAQ: MASI) announced today that Turgut Ozal Medical Centre Liver Hospital in Malatya, Turkey, has installed Masimo’s noninvasive, continuous haemoglobin (SpHb®) technology to monitor surgical patients.

SpHb is a breakthrough measurement that noninvasively and continuously measures total haemoglobin in the blood, and offers real-time visibility to changes – or lack of changes – in haemoglobin between invasive blood sampling. Laboratory haemoglobin values are only available intermittently and are often delayed. Clinicians can estimate blood loss, but this can both overstate and understate actual blood loss.1,2

“In many cases with severe bleeding during liver transplantation, we had to do the blood transfusion on the patient without having the opportunity to send a sample or the time required to obtain the results,” said Professor Dr. Hüseyin İlksen Toprak, anaesthesiologist at Turgut Ozal Medical Centre. “Sometimes, the amount of blood transfused exceeded that required by the patient. However, today, thanks to routine SpHb monitoring, I am able to immediately visualise both the level of bleeding and the therapeutic effect.”

SpHb monitoring may provide additional insight between invasive blood sampling when:

  • The SpHb trend is stable and the clinician may otherwise think haemoglobin is dropping
  • The SpHb trend is rising and the clinician may otherwise think haemoglobin is not rising fast enough
  • The SpHb trend is dropping and the clinician may otherwise think haemoglobin is stable

“In the area of liver transplantation, Turgut Ozal Medical Centre is recognised as one of the top five hospitals in the world,” stated Joe Kiani, Founder and CEO of Masimo. “Their hospital was designed to be one of the most modern in the country. They had already been using our SET® Measure-Through Motion and Low Perfusion pulse oximetry. We are happy to see them adopt SpHb technology through Masimo’s Root® patient monitoring and connectivity platform.”

The Turgut Ozal Medical Centre is in the campus of the Inonu University. The hospital has 16 floors, 1024 beds, 31 services, 12 intensive care units and 26 operating rooms. In addition to liver transplants, the medical centre also handles kidney transplants, bone marrow transplants and burn injuries.

In the U.S., Masimo rainbow® SET pulse co-oximeter instruments and sensors are indicated to provide noninvasive monitoring of arterial oxygen saturation (SpO2) and pulse rate (PR), carboxyhaemoglobin saturation (SpCO®), methaemoglobin saturation (SpMet®), total Haemoglobin concentration (g/dl SpHb), and/or respiration rate (RRa®). SpHb monitoring is intended to supplement, not replace, laboratory measurements. Blood samples should be analysed by laboratory instruments when possible prior to clinical decision making.

@MasimoInnovates| #Masimo

1 Eipe N et al. Indian Journal of Anesthesia. 2006; 50(1): 35-38.
2 Ram GG et al. Chin J Traumatol. 2014;17(4):225-8.

About Masimo

Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total haemoglobin (SpHb®), oxygen content (SpOC™), carboxyhaemoglobin (SpCO®), methaemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including: total haemoglobin (SpHb®) contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo.

Source: Masimo

Masimo
Irene Paigah, (858) 859-7001
irenep@masimo.com